menu
    • menu
    [{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase IV","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Impax Laboratories \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase IV","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase IV","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"IPX203","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"IPX203","moa":"DOPA decarboxylase","graph1":"Neurology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Levodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"IPX066","moa":"Dopamine precursor","graph1":"Neurology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IPX066","moa":"Dopamine precursor","graph1":"Neurology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Impax Laboratories \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Padagis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Impax Laboratories \/ Impax Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ Impax Laboratories"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Impax Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Impax Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Impax Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IPX159","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Impax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Impax Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Impax Laboratories \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Impax Laboratories

    Menu

    Impax Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

                            Details : Carbidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

                            Details : Carbidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2023

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPX203

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Part...

                            Details : IPX203 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2019

                            Lead Product(s) : IPX203

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPX203

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuati...

                            Details : IPX203 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2018

                            Lead Product(s) : IPX203

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

                            Details : Zonisamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2017

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levodopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

                            Details : Levodopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 02, 2017

                            Lead Product(s) : Levodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estradiol

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Padagis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

                            Details : Estradiol is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrophy.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            May 12, 2016

                            Lead Product(s) : Estradiol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Padagis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

                            Details : Carbidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2014

                            Lead Product(s) : Carbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPX159

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

                            Details : IPX159 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Restless Legs Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 31, 2012

                            Lead Product(s) : IPX159

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Impax Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPX066

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Saf...

                            Details : IPX066 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 08, 2011

                            Lead Product(s) : IPX066

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth